Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can adding interferon help clear hepatitis b virus?

NCT ID NCT02743182

Disease control Sponsor: José Antonio Carrion Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding pegylated interferon alfa-2a to standard nucleoside analogue therapy could help people with chronic hepatitis B lose the hepatitis B surface antigen (HBsAg). 119 adults with HBeAg-negative chronic hepatitis B who had been on nucleoside analogues for at least two years received 48 weeks of added interferon. The main goal was to see how many patients lost HBsAg one year after finishing treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pegylated interferon alfa-2a
What this could lead to
If successful, this approach could help more people with chronic hepatitis B achieve HBsAg loss, potentially reducing the need for lifelong medication.
What could go wrong
This is a small, early-phase study without a control group, so results may not be generalizable. Interferon can cause flu-like symptoms and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

119 people

The number who actually took part.

Start date

Jan 2015

Finished

Nov 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic hepatitis B (HBeAg-negative) * Signed inform consent * Aged \> 18 Exclusion Criteria: * Contraindications for Pegylated interferon (cirrhosis, pregnancy, others) * Previous treatment with interferon or Pegylated interferon * Previous HBsAg loss * Treatment duration with Nucleos(t)ide analogues less than 2 years * Poor adherence to Nucleos(t)ide analogues

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis B (hbeag-negative) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hepatitis B (hbeag-negative)